Biogen Signs Landmark RayThera Acquisition Worth Up to $1 Billion
CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 Biogen Inc. has announced a strategic agreement to acquire RayThera Inc....
Biogen
Advertisement
Biogen Highlights Kidney Disease Data at ERA and ATC 2026
CAMBRIDGE, Mass., June 3, 2026 Biogen Inc. announced that 14 abstracts from its expanding nephrology portfolio have been accepted...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
Biogen Reports Breakthrough Tau Therapy Alzheimer Data
CAMBRIDGE, Mass., May 14, 2026 Biogen Inc. has announced promising topline results from its Phase 2 CELIA study evaluating...
Eisai and Biogen Receive FDA Extension for LEQEMBI
TOKYO and CAMBRIDGE, Mass., May 8, 2026 Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and...
Advertisements
Biogen & TJ Biopharma Felzartamab Global Rights Deal
Cambridge, Massachusetts & Hangzhou, China, April 20, 2026 In a significant strategic move within the biopharmaceutical industry, Biogen Inc....
Alloy and Biogen Partner on Antisense Drug Platform
BOSTON, Massachusetts, United States, April 7, 2026 Alloy Therapeutics Inc. announced a multi-target collaboration and license agreement with Biogen...
Biogen to Acquire Apellis in $5.6B Strategic Pharma Deal
CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026 In a major biopharmaceutical industry consolidation, Biogen Inc. has...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
Advertisement
